JPRN-UMIN000015807招募中1 期
Phase I/II Study of TS-1/Oxaliplatin(SOX) for patients with unresectable advanced or recurrent gastric cancer - OCD1409 SOX
Gunma University Graduate School of Medicine0 个研究点目标入组 72 人开始时间: 2014年12月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) History of serious drug hypersensitivity 2) Pregnant, lactating or women of child-bearing potential. Men who want get partner pregnant 3) Active infections 4 4) Serious complications 5) Serious heart disease 6) Peptic ulcers 7) Sensory neuropathy 8) Diarrhea 9) A case with abdominal dropsy and the hydrothorax to need waste fluid by the sustained drainage custody 10) Brain metastasis 11) Other active malignancies (Nondisease period less than 5 years) 12) Continuous steroid treatment 13) Any other cases who are regarded as inadequate for study enrollment by the investigator 14) Administration contraindication of L-OHP , TS-1 , 5-F
研究者
相似试验
招募中
2 期
Phase II study of TS-1 / oxaliplatin(G-SOX) plus bevacizumab treatment for elderly advanced colorectal cancer patients.(GIANTS study)colorectal cancerJPRN-UMIN000009014niversity of Miyazaki Hospital.50
招募中
1 期
Phase I/II study of TS-1 / Oxaliplatin / Radiation for KRAS mutation type locally advanced and recurrent rectal cancer.Advanced or recurrent rectal cancerJPRN-UMIN000006305Graduate School of Medicine, Osaka Univesity31
未知
不适用
A feasibility study of TS-1 and oxaliplatin for Stage III gastric cancer in adjuvant settingGastric CancerJPRN-UMIN000023560Department of Surgical Oncology, Osaka City University Graduate School of Medicine40
已完成
2 期
A multicenter phase II trial of TS-1+oxaliplatin+panitumumab as first-line treatment in patients with kras-wild type unresectable advanced colorectal liver metastasis.colorectal cancerJPRN-UMIN000007236Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences2
已完成
1 期
Phase l and Phase ll Study of S-1+oxaliplatin (SOX)+cetuximab as first Line therapy in metastatic colorectal cancer with EGFR-detectable and KRAS wild typeMetastatic colorectal cancerJPRN-UMIN000007022Japan Clinical Cancer Research Organization56